If you have been reading about incretin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH. As of June 2011 Roche has obtained FDA approval for the INFORM HER2 Dual ISH DNA Probe cocktail developed by Ventana Medical Systems. The DDISH (Dual-chromagen/Dual-hapten In-situ hybridization) cocktail uses both HER2 and Chromosome 17 hybridization probes for chromagenic visualization on the same tissue section. The detection can be achieved by using a combination of ultraView SISH(silver in-situ hybridization) and ultraView Red ISH for deposition of distinct chromgenic precipitates at the site of DNP or DIG labeled probes.
=== Healthcare assistants/medicines counter assistants === In the UK, this group of staff can sell certain medicines (including pharmacy only and general sales list medicines) over the counter. They cannot prepare prescription-only medicines for supply to patients.
==== Cancer therapeutics ==== In 2022, over 1.9 million new cancer cases are projected in the U.S. alone. Nanogels are an attractive drug delivery solution for increasing both the efficacy of cancer therapeutics and their localization to cancer cells. Nanogels are currently being investigated for the treatment of different types of cancer, of which a few examples are listed here. In one study, chitosan-based nanogels loaded with doxorubicin, a chemotherapeutic, with a positive surface charge demonstrated a lower colorectal cancer cell viability compared to control groups and a similarly loaded nanogel with a negative surface charge. Another group conjugated folic acid to nanogels loaded with cisplatin or doxorubicin and delivered these therapeutics to ovarian cancer cells, which overexpress the folate receptor that binds with folic acid. These conjugated nanogels produced a significant decrease in tumor growth in a mouse model compared to vehicle controls and showed a site-specific delivery model for nanogels that may be effective for other types of cancer with upregulated folate receptors. Interestingly, gelatin-based nanogels loaded with cisplatin and conjugated to epidermal growth factor receptor (EGFR) ligands have been reported to successfully target lung cancer cells both in vitro and in vivo, with additional work confirming the effectiveness of these nanogels when transformed into aerosol particles.
== YouTube career == Pansino began her YouTube channel in 2010 after she was encouraged by a few of her friends who also worked on YouTube, and she started making videos to get more comfortable in front of a camera. After her early baking videos gained a steady following, viewers eventually started to request more content. Because she had never seen a baking show on television or the Internet, Pansino decided to create the Nerdy Nummies series. She decided to use the last name "Pansino" online, which was her maternal grandmother’s maiden name. She later revealed that in her early years of YouTube, while she was still working as an actress, she was given the ultimatum by her agent to choose between acting and YouTube. She remained adamant that she would not quit YouTube, despite the uncertainty involved. Pansino told Cosmopolitan in 2015: "At this point, I wasn't making any money on YouTube. I knew that it was possible to do that but I wasn't making a dime. I decided, I'm going to do this. I'm not going to let YouTube go." As of April 2026, Pansino's channel has attained over 5.1 billion views and 14.8 million subscribers, making it the most popular cooking channel on YouTube. She has received several accolades. In 2013, she won the Shorty Award for Best Foodie, Chef, or Food Lover in Social Media. She has also received five Streamy Award nominations for her work on Nerdy Nummies. In 2018, Pansino officially reached 10 million subscribers on YouTube, earning her the Diamond Play Button given by the company.
== Presentation == The most characteristic symptom of acrogeria is thin, atrophic skin with mottled pigmentation and telangiectasia, most severe in the limbs and extremities. This is accompanied by easy bruising, hyperkeratosis, and a loss of subcutaneous fat, which is replaced by connective tissue. Patients have a facies with a pinched face, hollow cheeks, prominent eyes without exophthalmos, a beak-like nose and thin lips. Though the hair and nails are normal in many cases, alopecia and nail dystrophies, such as onychogryphosis and koilonychia, have been reported. Stature is short in some patients and normal in others. The general skeletal structure is unremarkable, but acrogeria results in delayed closure of the cranial sutures, notching of the mandible, and micrognathia; and may also coincide with spina bifida, clubfoot and congenital dislocation of the hips. Sexual development, including the development of secondary sex characteristics, is normal, and so is intelligence. There is no correlation of acrogeria with metabolic, opthamological or cardiovascular disorders, and patients have a normal life expectancy. Similarities between the clinical features of acrogeria and Werner's syndrome have been observed.
Sources: en.wikipedia.org
=== Infection transmission === Semen can transmit many sexually transmitted infections and pathogens, including viruses like HIV and Ebola. Swallowing semen carries no additional risk other than those inherent in fellatio. This includes transmission risk for sexually transmitted infections such as human papillomavirus or herpes, especially for people with bleeding gums, gingivitis or open sores. Viruses in semen survive for a long time once outside the body.
Earlier studies found mean elimination rates of 15 mg/dL per hour for men and 18 mg/dL per hour for women, but Jones found 0.148 g/L/h and 0.156 g/L/h respectively. Although the difference between sexes is statistically significant, it is small compared to the overall uncertainty, so Jones recommends using the value 0.15 for the mean for all subjects. This mean rate is very roughly 8 grams of pure ethanol per hour (one British unit). Explanations for the gender difference are quite varied and include liver size, secondary effects of the volume of distribution, and sex-specific hormones. A 2023 study using a more complex two-compartment model with M-M elimination kinetics, with data from 60 men and 12 women, found statistically small effects of gender on maximal elimination rate and excluded them from the final model. At concentrations below 0.15-0.20 g/L, alcohol is eliminated more slowly and the elimination rate more closely follows first-order kinetics. The overall behavior of the elimination rate is described well by Michaelis–Menten kinetics. This change in behavior was not noticed by Widmark because he could not analyze low BAC levels. The rate of elimination of ethanol is also increased at very high concentrations, such as in overdose, again more closely following first-order kinetics, with an elimination half-life of about 4 or 4.5 hours (a clearance rate of approximately 6 L/hour/70 kg). This is thought to be due to increased activity of CYP2E1. Eating food in proximity to drinking increases elimination rate significantly, mainly due to increased metabolism.
=== 5 January === Ten people were killed in an SAF airstrike in Khartoum. The SAF and the JDF claimed to have deflected an RSF assault on El Fasher that came from the east and southeast of the city. The JDF also intercepted a weapons convoy for the RSF, arresting both Sudanese and Libyan nationals.
== Epidemiology == Approximately 34% of people with diabetes (Type 1 or Type 2 diabetes) will develop a foot ulcer in their lifetime. 18.6 million people worldwide will develop a foot ulcer each year. 15-20% of moderately to severely infected foot ulcers eventually lead to amputation, and the mortality rate of diabetic foot ulcers is 30% at 5 years with a mortality rate of 70% in those with a foot ulcer who receive an above the foot amputation. Foot ulcers and amputations are associated with a reduced quality of life. In the United States, Black people, Native Americans, Hispanics, and those living in rural areas or those with a lower socioeconomic status have an increased rate of amputations due to diabetic foot ulcers. Approximately 8.8 percent of hospital admissions of diabetic patients are for foot-related problems, and such hospital admissions are about 13 days longer than for diabetics without foot-related admissions. Approximately 58% of ulcers recur within 3 years and up to 65% recur within 5 years, sometimes at a different location that the original ulcer. Diabetic foot disease is the leading cause of non-traumatic lower limb amputations.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.